Cochrane Database Syst Rev. 2016 Jul 1; (6): 1–61 -Published online 2016 July 1
Le fonctionnement de la prise en charge des patients séropositifs au Bénin, le cas de l’Atacora
A all for global Action. The Oral Health Atlas. Second edition
Six months in, the indirect impacts of COVID-19 take a toll on health, social and economic outcomes.
An interdisciplinary approach to address global health challenges such as the Covid-19 pandemic, climate change, loss of biodiversity, human migration has been framed by the One Health approach. This approach is promoted at global level by the Tripartite of the World Health Organisation, the World A...nimal Health Organisation, the Food and Agriculture Organisation of the United Nations, recently joint by the United National Environment Program to form the Quadripartite. The German government through its Ministry of Economic Cooperation and Development supports this approach with its One Health strategy and investment in several technical cooperation projects.
more
Report of the Global Thematic Consultation on Population Dynamics
This ten year global plan for measles and rubella outlines the strategy that needs to be fully implemented to achieve the measles and rubella goals endorsed by the World Health Assembly. The plan sets out the: vision, goals and targets for the 2011-2020 period, recommended strategies, guiding princi...ples, priorities, costing of reaching the targets, and the challenges as well as ways to overcome them.
more
UNAIDS 2019, Reference
This edition of UNAIDS data shows the results of some of those successes, but also the challenges that remain. It contains the very latest data on the world’s response to HIV, consolidating a small part of the huge volume of data collected, analysed and refined by UNAIDS ov...er the years. The full data set of information for 1990 to 2018 is available on aidsinfo.unaids.org.
more
MICROBIAL DRUG RESISTANCEVolume 24, Number 5, 2018ªMary Ann Liebert, Inc.DOI: 10.1089/mdr.2017.0383
Antibiotic resistance (ABR) is a worldwide publichealth concern, with serious health, economic, and so-cietal repercussions. Its emergence is attributed to the se-lective pressure exerted by antib...iotic use in the community, hospitals, veterinary health, agriculture, aquaculture, and the environment. Additionally aggravating the situation is the fact that very few new antibiotics have recently been produced by pharmaceutical companies. It is widely acknowledged that food animals are key reservoirs of antibiotic-resistant bacteria and that antibiotic usage in this population favors the emergence, selection, and spread of resistance among animals and humans, both through zoonoses (infectious diseases trans-mitted between animals and humans) and the food chain.
more
This report presents examples from different agencies on how they approached community engagement in their Covid-19 responses, the tools and methodologies used, as well as the challenges they encountered and how they attempted to overcome these. It discusses what community engagement means to the va...rious agencies interviewed and in the literature consulted. And it puts forward some reflections on how CCCM and other sector agencies can take steps to ensure community participation in this and future pandemic responses.
more
The GFF needs an additional US$2.5 billion from 2021 to 2025 to enable countries to protect health gains and accelerate progress toward the 2030 Goals. Of this amount, the GFF urgently needs to secure new pledges of US$1.2 billion by the end of 2021 to help its current 36 partner countries protect ...and maintain essential health services and implement time-sensitive service delivery and health system improvements to enable a sharp bend of the curve back to a positive trajectory to close the gap to the SDGs.
more
Fact Book on WHO Level I and Level II monitoring indicators - To monitor the progress of efforts to improve the global medicines situation, WHO has developed a system of indicators that measure important aspects of a country’s pharmaceutical situation. Level 1 indicators measure the existence and ...performance of key national pharmaceutical structures and processes. Level II indicators measure key outcomes of these structures and processes in the areas of access, product quality and rational use. These indicators can be used to assess progress over time; to compare situations between countries; and to reassess and prioritize efforts based on the results.
This Fact Book gives the results of the assessment of Level I indicators conducted in 2003 and of Level II indicator surveys conducted between 2002 and 2004
more
Interim Recommendation published 19 September 2014. These recommendations reflect current understanding of Ebola virus disease (EVD) and are intended for national laboratory staff performing diagnostic testing to detect Ebola virus.